The Federal Trade Commission (FTC) is suing pharmacy benefit managers CVS Health (CVS), Cigna Group (CI), and UnitedHealth (UNH) over insulin prices, claiming that they have been artificially ...
The Federal Trade Commission (FTC) is suing pharmacy benefit managers CVS Health (CVS), Cigna Group (CI), and UnitedHealth (UNH) over insulin prices, claiming that they have been artificially ...
The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies ...
FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices – Includes Caremark, Express Scripts, ...
The Federal Trade Commission (FTC) filed a lawsuit Friday against three major prescription drug benefit managers (PBMs) and ...
Shares of Cigna Group CI sank 0.46% to $353.49 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.73% to 5,408.42 and Dow ...
Eli Lilly (NYSE:LLY) on Thursday announced that its QWINT-1 and QWINT-3 Phase 3 clinical trials for once-weekly insulin efsitora alfa reached the primary endpoints against daily basal insulins ...
In the phase 3 study, QWINT-1, efsitora was administered via four fixed doses once weekly in a single-use autoinjector in people with type 2 diabetes using basal insulin for the first time In a ...
Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly & Co.'s experimental once-weekly insulin can lower ...
The overall safety of insulin efsitora was similar to that of daily basal insulin therapies. Topline data were announced from 2 studies in the QWINT phase 3 clinical development program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback